Clinical trials: Pneumococcal Vaccine
Pneumococcal Disease
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
- Trial name
- NCT04642079
- Testing
- 20vPnC
- Where
- 43 sites in United States
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Respiratory Tract Diseases
Clinical Trial of Recombinant Pneumococcal Protein Vaccine
Streptococcus pneumoniae infections often cause serious health problems, especially in infants and the elderly. Failure to cover all polysaccharide types of vaccines is a greater problem for adults than for children.
- Conditions
- Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT05622942
- Testing
- PBPV, PPV23
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Type 1 Diabetes Mellitus
Protection Against Pneumococcal Infection in Children With T1DM
Children/ young people with diabetes may be at a higher risk of acquiring certain infections. These infections include those caused by a bacterium called the pneumococcus which can cause pneumonia, meningitis and ear infections.
- Trial name
- T1DM (NCT01939522)
- Testing
- 13-valent pneumococcal conjugate vaccine (PCV13)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Oxford
Influenza
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
The purpose of this study is to investigate the immunogenicity and safety when GSK Biologicals' influenza vaccine Influsplit™ Tetra (Fluarix™ Tetra) is co-administered with Merck \& Co.
- Trial name
- NCT02218697
- Testing
- Influsplit™ Tetra (Fluarix™ Tetra), Pneumovax™ 23
- Where
- 6 sites in Belgium, France
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
- Trial name
- NCT03574389
- Testing
- 13vPnC, Hib
- Where
- 2 sites in China
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis.
- Trial name
- NCT04168190
- Testing
- V116, Pneumovax™23
- Where
- 20 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Crohns Disease
Pneumococcal Vaccination of Crohn Patients
Inflammatory bowel disease (IBD) are at increased risk of infections. This increased susceptibility to infections is due to the disease itself, but also be-cause many patients with autoimmune conditions are treated with…
- Trial name
- PneuVAC (NCT01947010)
- Testing
- Prevenar 13, Pneumovax
- Where
- Denmark
- Volunteers
- 151 people
- Sponsor
- Statens Serum Institut
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer
Streptococcus Pneumoniae
PCV10 Immunogenicity Study Nepal 2015
A single centre open-label, parallel group, randomised controlled trial, recruiting healthy Nepalese infants aged 40-60 days, who present to the immunisation clinic at Patan Hospital, Kathmandu, Nepal, randomised to receive a…
- Trial name
- NCT02385513
- Testing
- 10-valent pneumococcal conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Immunocompromised Patients and Non-immunosuppressed Patients at Risk With an Indication for Pneumococcal Vaccination
Evaluation of Pneumococcal Vaccine Coverage
Pneumococcal infections are frequent and serious. Streptococcus pneumoniae is the leading cause of community-acquired pneumonia in adults.
- Trial name
- SAUVAC (NCT03597269)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acute Otitis Media, Otitis Media
Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Media in Swedish Children
The goal of this study is to look at the effect of pneumococcal conjugate vaccines (PCV) on physician-diagnosed otitis media (OM) and acute otitis media (AOM) incidence in Swedish children by collecting and analyzing patient…
- Trial name
- NCT02742753
- Testing
- Data collection
- Where
- Sweden
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Diseases
A Study to Evaluate 20vPnC in Healthy Chinese Infants
The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants.
- Trial name
- NCT07754539
- Testing
- 20vPnC, 13vPnC
- Where
- 4 sites in China
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Pfizer
Invasive Pneumococcal Disease
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
- Trial name
- NCT01128439
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Pneumococcal Vaccines, HIV
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent…
- Conditions
- Pneumococcal Vaccines, HIV, HIV Infections
- Trial name
- NCT00999739
- Testing
- Prevenar and Pneumo23
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Hospital Universitari Son Dureta
Pneumococcal Disease
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
- Trial name
- NCT06044077
- Testing
- 23-valent pneumococcal polysaccharide vaccine, control pneumococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 1,920 people, healthy volunteers welcome
- Sponsor
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Pneumococcal Infections, Streptococcal Infections
A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07648641
- Testing
- Previously vaccinated with PCV13 (CanSino), Previously vaccinated with PCV13 (Pfizer)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
This study will evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ when co-administered with DTPw-HBV/Hib and OPV or IPV vaccines, according to 2 different…
- Trial name
- NCT00344318
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Tritanrix-HepB
- Where
- 7 sites in Philippines, Poland
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Vaccine
Trial of Simplified Pneumococcal Vaccination in Vietnam II
This is a single-blind, open-label, randomised controlled trial with five groups. There are four different Pneumococcal Conjugate Vaccine (PCV) schedules to be evaluated.
- Trial name
- VPTII (NCT03098628)
- Testing
- PCV Vaccine
- Where
- Vietnam
- Volunteers
- 2,501 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Pneumococcal Infections, Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants. The primary hypotheses are that: 1) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114…
- Trial name
- PNEU-PED (NCT03893448)
- Testing
- V114, Prevnar 13™, RotaTeq™
- Where
- 81 sites in United States, Puerto Rico and 2 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline